Cargando…
Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study
BACKGROUND: Validity is the ability of an instrument to measure what it claims to measure. It means the degree to which the empirical evidence supports the trustworthiness of interpretations based on the calculated scores. The hematological malignancy (HM) specific patient reported outcome measure (...
Autores principales: | Goswami, Pushpendra, Oliva, Esther N., Ionova, Tatyana, Else, Roger, Kell, Jonathan, Fielding, Adele K., Jennings, Daniel M., Karakantza, Marina, Al-Ismail, Saad, Collins, Graham P., McConnell, Stewart, Langton, Catherine, Al-Obaidi, Magda J., Oblak, Metod, Salek, Sam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506039/ https://www.ncbi.nlm.nih.gov/pubmed/33013368 http://dx.doi.org/10.3389/fphar.2020.01308 |
Ejemplares similares
-
Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure: HM-PRO
por: Goswami, Pushpendra, et al.
Publicado: (2020) -
Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Content Validity
por: Goswami, Pushpendra, et al.
Publicado: (2020) -
Quality-of-life issues and symptoms reported by patients living with
haematological malignancy: a qualitative study
por: Goswami, Pushpendra, et al.
Publicado: (2020) -
Clinical Outcomes in Patients with Hematologic Malignancy (HM) and COVID-19
por: Cook, Michael Roderick, et al.
Publicado: (2020) -
P1700: EARLY APPEARANCE OF CARDIOTOXICITY, IN CHILDREN WITH HEMATOLOGICAL MALIGNANCIES (HM)
por: Antoniadi, K., et al.
Publicado: (2022)